Greg Bell answers the questions “What are some of the more significant structural changes that will shape our industry in the future?” and “Are pharmaceutical companies going to continue to be rewarded for innovation?” in a Future Pharmaceuticals article.
Counting the cost of carbon to shareholders: Taking first steps
Companies are facing the prospect of being taxed on greenhouse gas (GHG) emissions, which could reduce profitability and, ultimately, shareholder value. Our...